section name header

Evidence summaries

Propafenone for Supraventricular Tachycardia and Atrial Fibrillation

Propafenone is effective in terminating supraventricular tachycardia and atrial fibrillation in the majority of patients. The effectiveness in the suppression of arrhythmia is moderate, but it decreases over time. Level of evidence: "A"

A systematic review 1 including 60 studies, including acute termination of supraventricular tachycardia (SVT) (8 studies, 153 patients), chronic suppression of SVT (6 studies, 214 patients), acute termination of atrial fibrillation (AF) (27 studies, 1843 patients), and suppression of AF (25 studies, 1105 patients) was abstracted in DARE.

Propafenone successfully terminated 83.8% (95% CI 78.1 to 89.7) of supraventricular tachycardias, and the proportion of patients remaining in sinus rhythm without recurrent tachyarrhythmia at 1 year was 64.6% (95% CI 58.1 to 71.1%). The likelihood of converting a paroxysm of AF increased over time, with 76.1% (95% CI 72.8 to 79.4%) of patients in sinus rhythm at 24 hours after the initiation of therapy. Propafenone was effective in suppressing recurrences of AF in 55.4% (95% CI 51.3 to 59.7%) of instances at 6 months.

References

  • Reimold SC, Maisel WH, Antman EM. Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis. Am J Cardiol 1998 Oct 16;82(8A):66N-71N. [PubMed] [DARE]

Primary/Secondary Keywords